BMS at AHA Scientific Sessions 2021   

Intended for U.S. scientific audiences only.

At this year’s American Heart Association (AHA) Scientific Sessions, we’re looking forward to sharing updates from across our robust cardiovascular pipeline and portfolio. We will highlight key research programs that continue to propel discovery of treatment options for patients with cardiovascular disease around the world.

Hear from our CEO, Giovanni Caforio, M.D., about Bristol Myers Squibb’s presence at the AHA Scientific Sessions and the company’s commitment to patients living with cardiovascular disease.

Our Data at AHA 2021 

At the AHA Scientific Sessions 2021, Bristol Myers Squibb is presenting data from across our cardiovascular franchise, including Phase 2 data on our Factor XIa inhibitor, expanded data on our established Factor Xa inhibitor and important data that adds to a growing body of evidence for our cardiac myosin modulator.

For more than 60 years, Bristol Myers Squibb has been a trailblazer in the fight against cardiovascular disease; however, despite many advances, cardiovascular disease continues to be the leading cause of death globally. We are determined to fundamentally change how we approach prevention and treatment of cardiovascular disease in the future.

Our Science   

Hypertrophic cardiomyopathy: a Q&A with Marie-Laure Papi >

Learn more about hypertrophic cardiomyopathy (HCM), including why it is a priority area of study for researchers at Bristol Myers Squibb, from Marie-Laure Papi, vice president, development program lead, Cardiovascular Global Development.

Pioneering innovation in cardiovascular disease >

Hear from Vice President, Cardiovascular and Fibrosis Discovery Biology, David Gordon, on the story behind FXIa science and how Bristol Myers Squibb’s discoveries are advancing cardiovascular therapeutics.

Are you familiar with AFib symptoms and the increased risk of stroke associated with the condition? >

Learn about atrial fibrillation (AFib) and the No Time to Wait campaign, which aims in part to raise awareness about symptoms of the condition and the importance of talking to a healthcare provider.


Our cardiovascular research follows a science-driven pathway approach that delivers scientific innovation across key areas of focus.

Atrial fibrillation infographic >

Learn more about atrial fibrillation (AFib) signs & symptoms, detection and prevalence.